A computational algorithm for personalized medicine in schizophrenia
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 192, 131-136
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Mental Health (N01 MH900001)
- PI PF Sullivan (MH074027)
- by Eli Lilly and Company
This publication has 24 references indexed in Scilit:
- Genome-wide association studies in pharmacogenomicsPharmacogenetics and Genomics, 2013
- Genotype-Based Ancestral Background Consistently Predicts Efficacy and Side Effects across Treatments in CATIE and STAR*DPLOS ONE, 2013
- Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicineSchizophrenia Research, 2011
- Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionExpert Opinion on Drug Metabolism & Toxicology, 2010
- Finding the missing heritability of complex diseasesNature, 2009
- Genome-wide pharmacogenomic analysis of response to treatment with antipsychoticsMolecular Psychiatry, 2009
- Common polygenic variation contributes to risk of schizophrenia and bipolar disorderNature, 2009
- Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysisEuropean Journal of Human Genetics, 2009
- Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a frameworkMolecular Psychiatry, 2004
- A General Coefficient of Similarity and Some of Its Properties1971